Skip to main content

Day: August 7, 2023

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023 Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023 Daniel Faga appointed to the permanent position of president and chief executive officer Reiterating cash runway through year-end 2026 and updated expected year-end 2023 cash and investments of $380 – $395 millionSAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided...

Continue reading

BRT Apartments Corp. Reports Second Quarter 2023 Results

– Affirms Full Year 2023 Guidance – GREAT NECK, N. Y. , Aug. 07, 2023 (GLOBE NEWSWIRE) — BRT APARTMENTS CORP. (NYSE: BRT), a real estate investment trust that owns, operates, and, to a lesser extent, holds interests in joint ventures that own multi-family properties, today reported results for the second quarter ended June 30, 2023. HighlightsReported results for the second quarter of 2023 of net income of $11.2 million, or $0.58 per diluted share, Funds from Operations, or FFO, of $0.28 per diluted share and Adjusted Funds from Operations, or AFFO, of $0.37 per diluted share. Equity (loss) in earnings of unconsolidated joint ventures was $464,000 in the second quarter of 2023 and $(50,000) for the corresponding 2022 quarter. Combined Portfolio NOI increased 1.4% for the second quarter when compared with the prior-year period. Completed...

Continue reading

Par Pacific Holdings Reports Strong Second Quarter 2023 Results

HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) — Par Pacific Holdings, Inc. (NYSE: PARR) (“Par Pacific” or the “Company”) today reported its financial results for the quarter ended June 30, 2023.Net Income of $30.0 million, or $0.49 per diluted share Adjusted Net Income of $105.6 million, or $1.73 per diluted share Adjusted EBITDA of $150.8 million Exceptional operational and financial results from Billings in the first month after closingPar Pacific reported net income of $30.0 million, or $0.49 per diluted share, for the quarter ended June 30, 2023, compared to net income of $149.1 million, or $2.50 per diluted share, for the same quarter in 2022. Second quarter 2023 Adjusted Net Income was $105.6 million, compared to an Adjusted Net Income of $197.2 million in the second quarter of 2022. Second quarter 2023 Adjusted EBITDA was...

Continue reading

FreightCar America, Inc. Reports Second Quarter 2023 Results

Company delivers strong quarterly results realizing significant revenue growth and gross margin expansion Raises guidance for fiscal year 2023 CHICAGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer of railroad freight cars, today reported results for the second quarter ended June 30, 2023. Second Quarter 2023 HighlightsRevenues of $88.6 million on 760 railcar deliveries, up 56% compared to revenues of $56.8 million on 468 railcar deliveries in the second quarter of 2022 Gross margin of 14.6% with gross profit of $13.0 million, compared to gross margin of 11.6% with gross profit of $6.6 million in the second quarter of 2022 Net loss of ($18.9) million, or ($0.73) per share and Adjusted Net income of $2.7 million, or $0.02 per share,...

Continue reading

CrossAmerica Partners LP Reports Second Quarter 2023 Results

Allentown, PA, Aug. 07, 2023 (GLOBE NEWSWIRE) — CrossAmerica Partners LP Reports Second Quarter 2023 ResultsReported Second Quarter 2023 Net Income of $14.5 million, Adjusted EBITDA of $42.2 million and Distributable Cash Flow of $30.4 million compared to Second Quarter 2022 Net Income of $14.0 million, Adjusted EBITDA of $41.4 million and Distributable Cash Flow of $32.4 million Reported Second Quarter 2023 Gross Profit for the Wholesale Segment of $31.7 million compared to $33.5 million of Gross Profit for the Second Quarter 2022 and Second Quarter 2023 Gross Profit for the Retail Segment of $66.0 million compared to $55.5 million of Gross Profit for the Second Quarter 2022 Leverage, as defined in the CAPL Credit Facility, was 3.9 times as of June 30, 2023, compared to 4.5 times as of June 30, 2022 The Distribution Coverage...

Continue reading

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

First patients dosed in the BDC-1001 Phase 2 program BDC-1001 Phase 1 data presented at ASCO 2023 demonstrated favorable safety profile and encouraging efficacy as a monotherapy and in combination with nivolumab in HER2-expressing tumors BDC-3042 received IND clearance; clinical trial expected to start before year-end Cash balance of $157.1 million anticipated to fund key milestones through 2025REDWOOD CITY, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided an update on the continued advancement of its clinical programs. “We have extended our leadership position in immunotherapy as the first company...

Continue reading

Asure Announces Second Quarter 2023 Results

Reports Second Quarter Revenues of $30.4 Million, Up 50% from Prior Year Raises 2023 Financial Targets and Guidance AUSTIN, Texas, Aug. 07, 2023 (GLOBE NEWSWIRE) — Asure Software, Inc. (“we”, “us”, “our”, “Asure” or the “Company”) (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (“HCM”) software solutions, reported results for the second quarter ended June 30, 2023. Second Quarter 2023 Financial HighlightsRevenue of $30.4 million, up 50% from prior-year second quarter Recurring revenue of $23.0 million, up 21% from prior-year second quarter Net loss of $3.8 million, a $2.1 million improvement from prior-year second quarter EBITDA(1) of $3.3 million, up $3.4 million from prior-year second quarter Adjusted EBITDA(1) of $6.1 million, up $5.5 million from prior-year second quarter Gross profit of $22.0...

Continue reading

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance

Annual guidance increased to $132 million – $134 million, implying annual growth of 24%-26% SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2023. Recent HighlightsRecord worldwide revenue of $33.3 million for the second quarter 2023, representing approximately 30% growth over the corresponding period in 2022 Record U.S. revenue of $31.2 million for the second quarter 2023, representing approximately 31% growth over the corresponding period in 2022 Gross margin of 81% for the second quarter 2023 Approximately 935 U.S. active surgeons in the second quarter 2023, representing 30% growth over the corresponding period in 2022 Launch...

Continue reading

Beyond Meat® Reports Second Quarter 2023 Financial Results

EL SEGUNDO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Beyond Meat, Inc. (NASDAQ: BYND) (“Beyond Meat” or “the Company”), a leader in plant-based meat, today reported financial results for its second quarter ended July 1, 2023. Second Quarter 2023 Financial Highlights1Net revenues were $102.1 million, a decrease of 30.5% year-over-year. Gross profit was $2.3 million, or gross margin of 2.2% of net revenues, compared to a loss of $6.2 million, or gross margin of -4.2% of net revenues, in the year-ago period.Gross profit and gross margin were positively impacted by lower materials costs, lower inventory reserves and lower logistics costs per pound, partially offset by higher manufacturing costs excluding depreciation, which included the impact from flow-through of higher cost inventory produced in the fourth quarter of 2022, and...

Continue reading

Vivid Seats Announces Acquisition of Wavedash

Leading Online Ticket Marketplace Expands Global Reach into Japan CHICAGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today announced that it has entered into a definitive agreement to acquire WD Holdings Co., Ltd. (“WD Holdings” or “Wavedash”), an online ticket marketplace headquartered in Tokyo, Japan. Vivid Seats will acquire Wavedash for an enterprise value of approximately ¥‎8.7 billion, or approximately $61 million*, in cash. The transaction is expected to close in the third quarter of 2023, subject to regulatory requirements and other customary closing conditions. “Wavedash presents a strategically exciting and financially...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.